类有机物
食品药品监督管理局
药物开发
个性化医疗
精密医学
代理(哲学)
医学
药物发现
工程伦理学
业务
计算机科学
领域(数学)
临床实习
药品
基础研究
生物药物
计算生物学
数据科学
制药工业
药物反应
监管科学
制药工业
新兴技术
药理学
生物信息学
疾病
人类疾病
范式转换
作者
Huachao Li,Y. Pan,Zhibao Zheng,Renzhi Lin,Y. Pan,Lizhong Lin,Mingming Quan,Hongsheng Lu,Zhe Hu,Mingbin Zheng,Yihua Chen,Yuzhu Zhang
标识
DOI:10.1097/cm9.0000000000004067
摘要
Over the past decade, research associated with organoids has entered a golden era, marking a significant shift in the biomedical landscape. Organoids have been widely applied in the industrial sector and have gained recognition from regulatory authorities. However, amid this rapid expansion, a comprehensive and precise overview of the field has been lacking. Our review aims to fill this gap by presenting a comprehensive overview of the regulations and prospects for the development of investigational new drugs (INDs) using organoids. Drawing on our extensive experience in academic research and industrial applications, we meticulously analyzed the organoid field from two distinct perspectives. We explored the synergies between organoids and cutting-edge technologies such as single-cell omics, which highlights their crucial role in customizing personalized medicines, improving high-throughput drug screening, and establishing physiologically relevant disease models. Organoids offer advantages over traditional animal models, including high throughput, rapid results, cost-effectiveness, and strong clinical relevance. Our analysis delves into supportive policies from regulatory bodies such as the European Medicines Agency (EMA), Food and Drug Administration (FDA), and Center for Drug Evaluation (CDE) for the use of organoids. Our comprehensive analysis and reflective discourse provide a deep dive into the current landscape of drugs derived from organoids that have obtained IND status and the subsequent progress in clinical trials. We cautiously anticipate challenges and future directions in organoid research, particularly in terms of its potential impact on personalized patient care, novel avenues for drug discovery, and clinical research. In summary, our review presents a comprehensive exploration of organoid technology and prospects for the development of INDs using organoids, thereby providing reflections, summaries, and projections that can be beneficial for current researchers.
科研通智能强力驱动
Strongly Powered by AbleSci AI